TNF and inflammatory bowel disease: Our study revealed that the group of immunosuppressed IBD patients (treated with vedolizumab, ustekinumab, anti-TNF or azathioprine) and without a previous COVID-19 infection exhibited significantly lower mean anti-S-IgG levels compared to healthy control individuals after the third SARS-CoV-2 mRNA vaccination.